Learn More
During herpes simplex virus type 1 (HSV-1) neuronal latency, the only viral RNA detected is from the latency-associated transcript (LAT) gene. We have made a LAT deletion mutant of McKrae, an HSV-1 strain with a very high in vivo spontaneous reactivation rate. This mutant (dLAT2903) lacks the LAT promoter and the first 1.6 kb of the 5' end of LAT. dLAT2903(More)
Healing is an unfulfilled potential in the current healthcare system. Although illness is a ritual that necessitates the social support of natural networks and healers, the organization of hospitals impedes support and healing. In this article, the authors analyze the ritual of illness, the hospital as a technological bureaucracy, social networks, and(More)
Therapy of acute Herpes simplex keratitis in rabbits with idoxuridine-releasing ocular inserts showed that an application rate of 30mug/hr gave significantly better results than conventional treatment with idoxuridine drops and ointment while exposing the eye to 40% less drug. Delivery rates lower than this were equal or not as effective as drop and(More)
Using an in vitro system we measured the corneal epithelial cytotoxicity and the antiviral activity of the antiviral agents idoxuridine (IDU), trifluridine (TFT), ethyldeoxyuridine (EDU), and (E)-5-(2-Bromovinyl)-2'-deoxyuridine (BVDU). Confluent rabbit corneal epithelial cell cultures were established, and the antiviral agents were added for 5, 30, or 60(More)
Type I DNA restriction/modification systems are oligomeric enzymes capable of switching between a methyltransferase function on hemimethylated host DNA and an endonuclease function on unmethylated foreign DNA. They have long been believed to not turnover as endonucleases with the enzyme becoming inactive after cleavage. Cleavage is preceded and followed by(More)
Earlier studies on intraocular penetration of the antiviral drugs idoxuridine and vidarabine (formerly Ara A) reveal that either inactive metabolites from the former or very low levels of less active metabolites from the latter actually enter the aqueous. Additionally, to achieve therapeutic levels, systemically administered vidarabine must be given in(More)